

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Dock t No.	Serial N .
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		01-1720	09/993,211
COPY OF PAPERS ORIGINALLY FILED		Applicant:	JUL 05 2002
Asp, et al.	TECH CENTER 1600/2900		Group:
Filing Date:	November 16, 2001	1614	

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate


FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	N

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

EXAMINER <i>SM</i>	1.	Seymour, et al., "Use of dexrazoxane as a Cardioprotectant in Patients Receiving Doxorubicin or Epirubicin Chemotherapy for the Treatment of Cancer", The Provincial Systemic Treatment Disease Site Group, <i>Cancer Prev. Control</i> , 3(2):145-59, 1999
EXAMINER		DATE CONSIDERED <i>5/1/04</i>

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



Sheet 1 of 3

FORM PTO-1449
(R v. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket N .

Serial No.

01-1720

09/993,211

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900

Applicant:

Asp, et al.

Filing Date:

November 16, 2001

Group:

1614

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate


FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.).

Su J	1.	Imondi, et al., "Dose-Response Relationship of Dexrazoxane for Prevention of Doxorubicin-induced Cardiotoxicity in Mice, Rats and Dogs", <i>Cancer Research</i> , 56, pp. 4200-4204, 1996
	2.	Tetef, et al., "Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies", <i>Clinical Cancer Research</i> , Vol. 7, pp. 1569-1576, 2001
	3.	Keefe, "Anthracycline-Induced Cardiomyopathy", <i>Seminars in Oncology</i> , Vol. 28, No. 4, Suppl. 12, pp. 2-7, 2001
	4.	Herman, et al., "Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats", <i>Cancer Chemother Pharmacol</i> , 45, pp. 329-334, 2000
	5.	Della Torre, et al., "Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel", <i>Cancer Chemother Pharmacol</i> , 44, pp. 138-142, 1999
	6.	Speyer, et al., "Strategies for Reduction of Anthracycline Cardiac Toxicity", <i>Seminars in Oncology</i> , Vol. 25, No. 5, pp. 525-537, 1998
	7.	Chvetzoff, et al., "Prévention de la toxicité", <i>La Presse Médicale</i> , 27, no. 39, pp. 2106-2112, 1998 (including English abstract)
	8.	Herman, et al., "Preclinical Animal Models of Cardiac Protection from Anthracycline-Induced Cardiotoxicity", <i>Seminars in Oncology</i> , Vol. 25, No. 4, Suppl. 10, pp. 15-21, 1998
	9.	Swain, et al., "Delayed Administration of Dexrazoxane Provides Cardioprotection for Patients with Advanced Breast Cancer Treated with Doxorubicin-Containing Therapy", <i>Journal of Clinical Oncology</i> , Vol. 15, No. 4, pp. 1333-1340, 1997

J. Go 5/14/84




	Pouna, et al., "Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention", <i>British Journal of Pharmacology</i> , Vol. 117, pp. 1593-1599, 1996
	Venturini, et al., "Multicenter Randomized Controlled Clinical Trial to Evaluate Cardioprotection of Dexrazoxane Versus No Cardioprotection in Women Receiving Epirubicin Chemotherapy for Advanced Breast Cancer", <i>Journal of Clinical Oncology</i> , Vol. 14, No. 12, pp. 3112-3120, 1996
12.	Dorr, "Cytoprotective Agents for Anthracyclines", <i>Seminars in Oncology</i> , Vol. 23, No. 4, Suppl. 8, pp. 23-34, 1996
13.	Shan, et al., "Anthracycline-Induced Cardiotoxicity", <i>Ann Intern Med.</i> , 125:47-58, 1996
14.	Cook-Bruns, "Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer", <i>Oncology</i> , 61 (suppl 2):58-66, 2001
15.	Winer, et al., "New Combinations with Herceptin® in Metastatic Breast Cancer", <i>Oncology</i> , 61 (suppl 2):50-57, 2001
16.	Ewer, et al., "Cardiotoxicity in Patients Receiving Trastuzumab (Herceptin): Primary Toxicity, Synergistic or Sequential Stress, or Surveillance Artifact?", <i>Seminars in Oncology</i> , Vol. 26, No. 4, Suppl. 12, pp. 96-101, 1999
17.	Sparano, "Cardiac Toxicity of Trastuzumab (Herceptin): Implications for the Design of Adjuvant Trials", <i>Seminars in Oncology</i> , Vol. 28, No. 1, Suppl. 3, pp. 20-27, 2001
18.	Chien, "Myocyte Survival Pathways and Cardiomyopathy: Implications for Trastuzumab Cardiotoxicity", <i>Seminars in Oncology</i> , Vol. 27, No. 6, Suppl. 11, pp. 9-14, 2000
19.	Schnitt, "Breast Cancer in the 21 st Century: New Opportunities and New Challenges", <i>Modern Pathology</i> , Vol. 14, No. 3, pp. 213-218, 2001
20.	Untch, et al., "Anthracycline and Herceptin® als neue Therapieoption beim metastasierten Mammakarzinom", <i>Onkologie</i> , 23 (suppl 2):15-19, 2000
21.	Schaller, et al., "Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein", <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 125, pp. 520-524, 1999
22.	Doroshov, et al., "Reactive Oxygen Metabolism Induced by Trastuzumab (Herceptin®) in Human Breast Cancer Cells", <i>Molecular Biology</i> , 29, #4145
23.	Mladosiévičová, et al., "Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane", <i>Neoplasma</i> , Vol. 48, No. 1, pp. 61-99, 2001
24.	Anderson, "Which goes first, the electron or the proton?", <i>Redox Report</i> , Vol. 5, No. 6, Commentary
25.	Kwok, et al., "The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity", <i>Redox Report</i> , Vol. 5, No. 6, pp. 317-324, 2000
26.	Lopez, "Dexrazoxane - Attualità e prospettive nella protezione dalla cardiotossicità indotta da chemioterapia", <i>Clin. Ter.</i> , 150:37-49, 1999
27.	Ferrans, et al., "Pathogenesis and Prevention of Doxorubicin Cardiomyopathy", <i>Cardiology</i> , Vol. 88, No. 10, pp. 928-937, 1997
28.	Rosing, et al., "Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane® and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)", <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , Vol. 24, No. 1, pp. 69-77, 1999
29.	Baldwin, et al., "Dose-Independent Pharmacokinetics of the Cardioprotective Agent Dexrazoxane in Dogs", <i>Biopharmaceutics & Drug Disposition</i> , Vol. 17, pp. 541-550, 1996
30.	Kosty, et al., "High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study - Cancer and Leukemia Group B 9631", <i>Lung Cancer</i> , Vol. 34, pp. 289-295, 2001
31.	Weiss, et al., "Dexrazoxane (ICRF-187)", <i>Gen. Pharmac.</i> , Vol. 32, No. 1, pp. 155-158, 1999
32.	Hasinoff, et al., "Relative Plasma Levels of the Cardioprotective Drug Dexrazoxane and its Two Active Ring-Opened Metabolites in the Rat", <i>Drug Metabolism and Disposition</i> , Vol. 27, No. 2, 1999
33.	Seymour, et al., "Use of dexrazoxane as a Cardioprotectant in Patients Receiving Doxorubicin or Epirubicin Chemotherapy for the Treatment of Cancer", <i>The Provincial Systemic Treatment Disease Site Group, Cancer Prev. Control</i> , 3(2):145-59, 1999 - Abstract Only
34.	Kvina, et al., "Preclinical comparison of bis-diketopiperazine-propane (dexrazoxane) and bis-diketopiperazine-ethane (antimet) on the adriamycin-cardiotoxic effect", <i>Neoplasma</i> , Vol. 44, No. 2, pp. 97-99, 1997

A. G. 5/14/04

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900

FORM PTO-1449
(R v. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket N .

01-1720

Serial No.

09/993,211

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use several sheets if necessary)**Applicant:**

Asp, et al.

Filing Date:

November 16, 2001

Group:

1614

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

1	Hasinoff, et al., "Chemical, Biological and Clinical Aspects of Dexrazoxane and Other Bisdioxopiperazines", <i>Current Medicinal Chemistry</i> , 5, p. 1-28, 1998
2	Lopez, et al., "Randomized Prospective Clinical Trial of High-Dose Epirubicin and Dexrazoxane in Patients with Advanced Breast Cancer and Soft Tissue Sarcomas", <i>J. Clin. Oncol.</i> Vol. 16, No. 1, pp. 86-92, 1998
3	Vici, et al., "Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment", <i>Clin. Ter.</i> , 149, pp. 15-20, 1998
4	Imondi, "Preclinical Models of Cardiac Protection and Testing for Effects of Dexrazoxane on Doxorubicin Antitumor Effects", <i>Semin. Oncol.</i> Vol. 25, No. 4, Suppl. 10, pp. 22-30, 1998
5	Lopez, et al., "European Trials with Dexrazoxane in Amelioration of Doxorubicin and Epirubicin-Induced Cardiotoxicity", <i>Semin. Oncol.</i> Vol. 25, No. 4, Suppl. 10, pp. 55-60, 1998
6	Hochster, "Clinical Pharmacology of Dexrazoxane", <i>Semin. Oncol.</i> , Vol. 25, No. 4, Suppl. 10, pp. 37-42, 1998
7	Von Hoff, "Phase I Trials of Dexrazoxane and Other Potential Applications for the Agent", <i>Semin. Oncol.</i> , Vol. 25, No. 4, Suppl. 10, pp. 31-36, 1998

RECEIVED
JUN 18 2002
TECH CENTER 1600/2900

8 Hellmann, "Overview and Historical Development of Dexrazoxane", *Semin. Oncol.*, Vol. 25, No. 4, Suppl. 10, pp. 48-54, 1998

9 Wexler, "Ameliorating Anthracycline Cardiotoxicity in Children with Cancer: Clinical Trials with Dexrazoxane", *Semin. Oncol.*, Vol. 25, No. 4, Suppl. 10, pp. 86-92, 1998

10 Synold, et al., "Antineoplastic Activity of Continuous Exposure to Dexrazoxane: Potential New Role as a Novel Topoisomerase II Inhibitor", *Semin. Oncol.*, Vol. 25, No. 4, Suppl. 10, pp. 93-99, 1998

11 Wiseman, et al., "Dexrazoxane: A Review of its Use as a Cardioprotective Agent in Patients Receiving Anthracycline-Based Chemotherapy", *Drugs*, 56 (3): pp. 385-403, 1998

12 Della Torre, et al., "Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane", *Cancer Chemother Pharmacol*, 43, pp. 151-156, 1999

13 O'Donnell, et al., "A Phase I Trial of the VEGF Inhibitor SU5416, Incorporating Dynamic Contrast MRI Assessment of Vascular Permeability", *685, *Proceedings of ASCO, Clinical Pharmacology*, Volume 19, p. 177a, 2000

14 Baselga, et al., "Continuous Administration of ZD1839 (Iressa), a Novel Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), in Patients with Five Selected Tumor Types: Evidence of Activity and Good Tolerability", *686, *Proceedings of ASCO, Clinical Pharmacology*, Volume 19, p. 177a, 2000

15 Stewart, et al., "Population Pharmacokinetics of Topotecan in Children and Adolescents", *687, *Proceedings of ASCO, Clinical Pharmacology*, Volume 19, p. 177a, 2000

16 Lewis, et al., "A Phase-I Study of the Novel Topoisomerase-I Inhibitor J-107088 Administered on a Multiple-Dose Schedule", *688, *Proceedings of ASCO, Clinical Pharmacology*, Volume 19, p. 177a, 2000

17 Garrison, et al., "A Phase I and Pharmacokinetic Study of the Camptothecin (CPT) Analog DX-89511 (Exetecan Mesylate): Escalating Infusion Duration and Dose", *765, *Proceedings of ASCO, Clinical Pharmacology*, Volume 19, p. 197a, 2000

18 Houghton, et al., "Anticancer Activity of the Novel DB-67 Silatecan, a Highly Lipophilic Liposomal Camptothecin Agent Displaying Improved Intrinsic Human Blood and Plasma Stability and Potent Topoisomerase I Activity", *766, *Proceedings of ASCO, Clinical Pharmacology*, Volume 19, p. 197a, 2000

19 Peck, Phase I Trial of J-107088, a Novel Topoisomerase I Inhibitor, Administered Once Every 21 Days", *767, *Proceedings of ASCO, Clinical Pharmacology*, Volume 19, p. 197a, 2000

20 Bos, et al., "Phase I Study of NX 211 (Liposomal Lurtotecan) Administered as a Single Dose Every 3 Weeks", *768, *Proceedings of ASCO, Clinical Pharmacology*, Volume 19, p. 197a, 2000

21 Swain, et al., "Cardioprotection with Dexrazoxane for Doxorubicin-Containing Therapy in Advanced Breast Cancer", *Journal of Clinical Oncology*, Vol. 15, No. 4, pp. 1318-1332, 1997

22 Gianni, "Tolerability in patients receiving trastuzumab with or without chemotherapy", *Annals of Oncology*, 12 (Suppl. 1): S63-S68, 2001

23 Imondi, et al., "Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs", *Cancer Research*, Abstract, 56 (18):4200, 1996

24 Baldwin, et al., "Dose-Independent Pharmacokinetics of the Cardioprotective Agent Dexrazoxane in Dogs", *Biopharmaceutics & Drug Disposition*, Article Abstract, Vol. 17, Issue 6, pp. 541-550, 1996

25 Maliszka, et al., "Inhibition of Anthracycline Semiquinone Formation by ICRF-187 (Dexrazoxane) in cells", *Free Radical Biology & Medicine*, Vol. 20, No. 7, pp. 905-914, 1996

26 Bates, et al., "A Pharmacoeconomic Evaluation of the Use of Dexrazoxane in Preventing Anthracycline-Induced Cardiotoxicity in Patients with Stage IIB or IV Metastatic Breast Cancer", *Clinical Therapeutics*, Vol. 19, No. 1, pp. 167-184 1997

27 Woodlock, et al., "Coincident Acute Myelogenous Leukemia and Ischemic Heart Disease: Use of the Cardioprotectant Dexrazoxane During Induction Chemotherapy", *American Journal of Hematology*, 59, pp. 246-248 1998

28 Sawyer, et al., "Daunorubicin-Induced Apoptosis in Rat Cardiac Myocytes is Inhibited by Dexrazoxane", *Original Contributions*, pp.257-265, * American Heart Association, Inc. 1999

29 Okubo, et al., "Synthesis and Biological Activities of NB-506 Analogues Modified at the Glucose Group", *Bioorganic & Medicinal Chemistry Letters*, Vol. 10, pp. 419-422, 2000

30 Long, et al., "Non-camptothecin topoisomerase I active compounds as potential anticancer agents", *Expert Opinion on Therapeutic Patents*, 10(5), pp. 635-666, 2000

EXAMINER	DATE CONSIDERED 5/14/04
----------	-------------------------

RECEIVED

JUN 18 2002

TECH CENTER 1600/2900